Arcturis and Akrivia, two companies focused on leveraging NHS patient data for drug development and research, have agreed to merge in a deal valued at £140 million. The combined entity aims to enhance drug discovery and development by integrating their specialized real-world health datasets.
The merger of Arcturis and Akrivia Health aims to create a more powerful platform for drug development by combining specialized NHS patient data, potentially accelerating the creation of new treatments for various diseases.
Two companies that utilize National Health Service (NHS) patient data for drug development and research, Arcturis and Akrivia Health, have announced a merger valued at £140 million. The deal is set to combine their specialized datasets to accelerate the discovery, development, and launch of new therapies.
Akrivia Health focuses on creating comprehensive real-world datasets for mental health and dementia, including electronic health records from 20 NHS Trusts, covering 6.3 million patients. Their data includes structured information and natural language processing (NLP) from clinical notes, offering deep psychiatric data and linkage with primary care records. They also provide access to GP records covering 20% of the UK population and hospital activity data.
Arcturis, on the other hand, specializes in curating enhanced electronic patient records enriched with unstructured, molecular, and genetic data. Their mission is to empower drug development through precision real-world health data, offering access to unstructured data via NLP, laboratory findings, biomarkers, prescribing data, genetic data, and imaging reports. Arcturis emphasizes tailoring its data to specific research needs to generate bespoke insights.
The combined entity aims to leverage these distinct but complementary datasets to provide a more robust and comprehensive offering for pharmaceutical and biotechnology companies.